(Q38010810)

26 August 2017

title

Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement (English)

1 reference

26 August 2017

1 reference

13

A Bufe

1 reference

26 August 2017

M A Calderon

1

1 reference

26 August 2017

R Gerth van Wijk

2

1 reference

26 August 2017

I Eichler

3

1 reference

26 August 2017

P M Matricardi

4

1 reference

26 August 2017

E M Varga

5

1 reference

26 August 2017

M V Kopp

6

1 reference

26 August 2017

P Eng

7

1 reference

26 August 2017

B Niggemann

8

1 reference

26 August 2017

A Nieto

9

1 reference

26 August 2017

E Valovirta

10

1 reference

26 August 2017

P A Eigenmann

11

1 reference

26 August 2017

G Pajno

12

1 reference

26 August 2017

S Halken

14

1 reference

26 August 2017

K Beyer

15

1 reference

26 August 2017

U Wahn

16

1 reference

26 August 2017

European Academy of Allergy and Clinical Immunology

17

1 reference

26 August 2017

publication date

1 June 2012

1 reference

Pediatric Allergy & Immunology

26 August 2017

published in

1 reference

26 August 2017

volume

23

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

300-306

1 reference

Evidence of effect of subcutaneous immunotherapy in children: complete and updated review from 2006 onward.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Close collaboration between academia, industry and drug regulators is required in the development of allergen products for specific immunotherapy in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Recommendations for appropriate sublingual immunotherapy clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

The natural history of allergic rhinitis in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Dynamic evolution of serum immunoglobulin E to airborne allergens throughout childhood: results from the Multi-Centre Allergy Study birth cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Long-term clinical and immunological effects of allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

GA² LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Immunotherapy: The meta-analyses. What have we Learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Systematic reviews of sublingual immunotherapy (SLIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Specific immunotherapy in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Evaluation of near-fatal reactions to allergen immunotherapy injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Specific immunotherapy in children: the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Specific allergy immunotherapy for allergic rhinitis: subcutaneous and sublingual

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Long-term efficacy of preseasonal grass pollen immunotherapy in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Design and Recruitment for the GAP Trial, Investigating the Preventive Effect on Asthma Development of an SQ-Standardized Grass Allergy Immunotherapy Tablet in Children with Grass Pollen–Induced Allergic Rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Epidemiology of food allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Provoking allergens and treatment of anaphylaxis in children and adolescents--data from the anaphylaxis registry of German-speaking countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

NIAID-sponsored 2010 guidelines for managing food allergy: applications in the pediatric population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Oral immunotherapy for food allergy in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Future therapies for food allergies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

The safety and efficacy of sublingual and oral immunotherapy for milk allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3038.2012.01313.X

10.1111/J.1399-3038.2012.01313.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference